DERM - Dermira, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.59
+0.16 (+1.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close12.43
Open12.42
Bid11.06 x 3100
Ask13.00 x 1400
Day's Range12.22 - 12.76
52 Week Range6.98 - 31.42
Volume430,152
Avg. Volume451,393
Market Cap529.112M
Beta (3Y Monthly)2.25
PE Ratio (TTM)N/A
EPS (TTM)-7.62
Earnings DateAug 7, 2017 - Aug 11, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Report: Exploring Fundamental Drivers Behind Dermira, California Resources, OGE Energy, Oasis Petroleum, Harmonic, and CBIZ — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire9 days ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on October 8, 2018, the company granted inducement awards to nine new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 8,250 shares of Dermira common stock and stock options to purchase an aggregate of 44,825 shares of Dermira common stock.

  • GlobeNewswire16 days ago

    Dermira and Christian Siriano Collaborate to Inspire People Living with Excessive Underarm Sweating to Feel Confident in Their Own Skin

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced its collaboration with Council of Fashion Designers of America, Inc. (CFDA) fashion designer Christian Siriano for the Check Your Sweat educational campaign. Check Your Sweat is designed to raise awareness of excessive underarm sweating, or primary axillary hyperhidrosis, a treatable medical condition.

  • GlobeNewswire17 days ago

    Dermira’s QBREXZA™ (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide for the Treatment of Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that QBREXZA™ (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

  • GlobeNewswire23 days ago

    Dermira to Present at Cantor 2018 Global Healthcare Conference

    MENLO PARK, Calif., Sept. 25, 2018-- Dermira, Inc., a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions ...

  • GlobeNewswirelast month

    Dermira Presents New Pediatric Efficacy and Safety Data for Glycopyrronium Tosylate in Patients with Primary Axillary Hyperhidrosis at the European Academy of Dermatology and Venereology Congress

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today presented data from a post-hoc analysis of the Phase 3 open-label ARIDO study which evaluated the long-term safety of glycopyrronium tosylate in patients with primary axillary hyperhidrosis. The data showed the response of pediatric patients (ages 9 to 16) compared to older patients (ages 17 years and older) with primary axillary hyperhidrosis who received treatment with glycopyrronium tosylate (now QBREXZA™ (glycopyrronium) cloth).

  • GlobeNewswirelast month

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on September 7, 2018, the company granted inducement awards to 116 new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 35,550 shares of Dermira common stock and stock options to purchase an aggregate of 77,775 shares of Dermira common stock.

  • GlobeNewswirelast month

    Dermira Provides Launch Readiness Update for QBREXZA™ (glycopyrronium) Cloth for Primary Axillary Hyperhidrosis

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, today announced several updates related to the upcoming launch and availability of QBREXZA™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients 9 years of age and older. Primary axillary hyperhidrosis, also known as excessive underarm sweating, is a chronic medical skin condition that results in sweating beyond what is needed for normal body temperature regulation. “QBREXZA is the culmination of more than 10 years of clinical development work,” said Tom Wiggans, chairman and chief executive officer of Dermira.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind MediciNova, Dermira, FRP, BiondVax Pharmaceuticals, The Descartes Systems Group, and American Software — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MediciNova, ...

  • GlobeNewswire2 months ago

    Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that on August 7, 2018, the company granted inducement awards to six new employees. The grants were made pursuant to Dermira’s 2018 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Dermira and were approved by the Compensation Committee of Dermira’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted restricted stock unit awards (RSUs) representing an aggregate of 6,250 shares of Dermira common stock and stock options to purchase an aggregate of 34,600 shares of Dermira common stock.

  • Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Dermira (DERM) Reports Q2 Loss, Tops Revenue Estimates

    Dermira (DERM) delivered earnings and revenue surprises of 0.00% and 0.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire2 months ago

    Dermira Reports Second Quarter 2018 Financial Results and Provides Corporate Update 

    -QBREXZA™ cloth for the treatment of primary axillary hyperhidrosis approved in June 2018- QBREXZA expected to be available nationwide in pharmacies beginning in October 2018- Lebrikizumab Phase 2 b enrollment ...

  • Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval
    Zacks3 months ago

    Dermira (DERM) Gains 5% in a Week, Post-Qbrexa Approval

    Shares of Dermira, Inc. (DERM) increase about 5% after the FDA approved its excessive underarm sweating drug, Qbrexza.

  • Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?
    Zacks4 months ago

    Are Options Traders Betting on a Big Move in Dermira (DERM) Stock?

    Investors in Dermira (DERM) need to pay close attention to the stock based on moves in the options market lately.

  • FDA Approval Pushes Dermira’s Stock Price Up
    Market Realist4 months ago

    FDA Approval Pushes Dermira’s Stock Price Up

    Today, Dermira (DERM) announced FDA approval for its Qbrexza™ (glycopyrronium) cloth as a treatment option for primary axillary hyperhidrosis or excessive armpit sweating in both adults and pediatric patients above nine years of age. After this announcement, Dermira rose around 5.6% in the morning trading. Dermira estimates that almost 15 million people in the United States suffer from hyperhidrosis, of which 10 million suffer from axillary hyperhidrosis.

  • ACCESSWIRE4 months ago

    Free Daily Technical Summary Reports on Dermira and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / June 18, 2018/ If you want a free Stock Review on DERM sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Daré Bioscience Inc. (NASDAQ: DARE), Dermira Inc. (NASDAQ: DERM), Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA), and Egalet Corp. (NASDAQ: EGLT).

  • ACCESSWIRE5 months ago

    Dermira, Upcoming FDA Decision on NDA, Analyst Review and Target

    NEW YORK, NY / ACCESSWIRE / May 31, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is initiating coverage on Dermira, Inc. (DERM) is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Earlier in May, the company provided an update on its clinical development programs. For the past eight years, Dermira has been working towards its goal of offering new therapies for the millions of patients living with chronic skin conditions.

  • ACCESSWIRE5 months ago

    Wired News - Reata Pharma Presented Encouraging Interim Data from PHOENIX Trial Assessing Bardoxolone Methyl in Patients with ADPKD and IgA Nephropathy

    LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want access to our free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RETA as the Company's latest news hit the wire. On May 25, 2018, the Company announced that it has presented results from the ongoing, open-label, Phase-2 PHOENIX trial assessing bardoxolone methyl (bardoxolone) in patients with autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy cohorts at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) meeting in Copenhagen.

  • Here's Why Dermira Inc Stock Fell More Than 23% Today
    Motley Fool5 months ago

    Here's Why Dermira Inc Stock Fell More Than 23% Today

    The company hosted its 2018 analyst and investor day. It didn't go well.